EDAP TMS SA to Announce First Quarter 2021 Financial Results on May 11, 2021

Rhea-AI Summary

EDAP TMS SA (Nasdaq: EDAP) will release its first-quarter financial results for the period ending March 31, 2021, on May 11, 2021, after market close. A conference call and webcast will follow on May 12, 2021, at 8:30 am EDT, featuring remarks from Marc Oczachowski, CEO, and François Dietsch, CFO. EDAP TMS is a leader in robotic energy-based therapies and develops innovative medical devices for prostate cancer treatment. The company aims to provide comprehensive solutions from diagnosis to treatment within the therapeutic ultrasound market.

Positive

• Strong position in the robotic energy-based therapies market.
• Comprehensive solutions for prostate cancer treatment with Focal One® and ExactVu™.

Negative

• None.

Company to host conference call and webcast on Wednesday, May 12 at 8:30 am EDT

LYON, France, May 4, 2021 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2021 after the markets close on Tuesday, May 11, 2021.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, May 12, 2021. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Wednesday, May 12^th @ 8:30am Eastern Time
Domestic:                877-451-6152
International:                201-389-0879
Passcode:                13718852
Webcast:                http://public.viavid.com/index.php?id=144433

About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com

 

FAQ

When will EDAP TMS release its first quarter financial results?

EDAP TMS will release its first quarter financial results on May 11, 2021, after market close.

What is the date and time of EDAP TMS's conference call?

The conference call will take place on May 12, 2021, at 8:30 am EDT.

Who will participate in EDAP TMS's conference call?

Marc Oczachowski, CEO, and François Dietsch, CFO, will be participating in the conference call.

What is the focus of EDAP TMS's product offerings?

EDAP TMS focuses on robotic energy-based therapies and medical devices for prostate cancer treatment.